- Biopreservation Tools, Inc. provides biopreservation media and services to help clients preserve cells, tissues, and organs. Their goal is to facilitate research and development of new biologic therapies.
- They have over 600 customers across 33 countries working in areas like regenerative medicine, drug discovery, and biobanking. Their media products and cold chain shipping containers aim to maximize viability of biologic materials.
- The presentation outlines their product portfolio and strategy to target growth opportunities in key regenerative medicine, drug discovery, and biobanking markets over the next several years.
QPS is a contract research organization that specializes in developing close relationships with clients based on trust and mutual respect. They offer flexible and nimble clinical work to improve outsourced work quality and reduce oversight needs. Their biosimilar drug development expertise can help clients advance their biosimilar portfolios in a timely manner for the benefit of patients worldwide.
Dyadic International is developing its C1 gene expression platform to more accessibly and affordably produce biologic vaccines and drugs. C1 uses a proprietary fungal system that offers higher productivity, lower costs, and a faster development timeline compared to the commonly used CHO system. Dyadic has collaborative research programs underway with companies like Sanofi and Mitsubishi Tanabe Pharma to evaluate C1 for producing various biologics. The company aims to license its C1 technology to partners in order to disrupt biomanufacturing and address the growing demand for more affordable biologic treatments.
COVID-19 Impacts on the Global mRNA Vaccines and Therapeutics Market NarayanSharma67
The “Global mRNA Vaccines and Therapeutics Market” is likely to grow at a CAGR of around 13% during the forecast period, i.e., 2021-26, says MarkNtel Advisors. The market growth essentially attributes to the rising prevalence of infectious and chronic diseases, including HIV, diabetes, cancer, and cardiovascular diseases.
Dyadic International is a global biotechnology company focused on improving and applying its proprietary C1 gene expression platform, a patented genetically modified strain of the fungus Myceliophthora thermophila, to address opportunities in human and animal health markets. The C1 platform can help bring biologic drugs to market faster, in greater volumes, and at lower cost than existing platforms like CHO cells. Dyadic pursues R&D collaborations and licensing arrangements to develop and manufacture biopharmaceuticals using the C1 platform.
Becton Dickinson & Company: VACUTAINER Systems DivisionZach Evans
Becton Dickinson & Company (BD) was formed in 1897 by Maxwell Becton and Fairleigh Dickinson as a medical device import company. In 1980, BD formed its VACUTAINER Systems Division (BDVS) to focus on blood collection products. By the mid-1980s, BDVS had an estimated 80% market share in the US but faced pressures from declining hospital testing and group purchasing organizations seeking single suppliers and private label products. BDVS needed to determine the best price and distribution strategy to address these market changes.
Leading Molecules to Market - An overview on licensingBananaIP Counsels
Leading Molecules to Market - An overview on licensing
Contact Us for Intellectual Property Services
BananaIP Counsels
Regd Office
No.40,3rd Main Road,JC Industrial Estate,
Kanakapura Road,Bangalore – 560 062.
Email: contact@bananaip.com
Telephone: +91-80-26860414 /24/34
Reducing technical and regulatory uncertinty in biosimilar developmentAjaz Hussain
Reducing risk of Biosimilar product development requires early attention to evidence development and effective communication to multiple stakeholders. Skill set for effective leadership and management, in the US market context, includes ability to: (1) Overcome the ‘blind spots’, (2) Analysis of knowledge, and (3) Evidence logic & communication. This presentation makes these points while comparing the EU and the USA regulatory context and the challenges of integration across multiple scientific and clinical disciplines.
QPS is a contract research organization that specializes in developing close relationships with clients based on trust and mutual respect. They offer flexible and nimble clinical work to improve outsourced work quality and reduce oversight needs. Their biosimilar drug development expertise can help clients advance their biosimilar portfolios in a timely manner for the benefit of patients worldwide.
Dyadic International is developing its C1 gene expression platform to more accessibly and affordably produce biologic vaccines and drugs. C1 uses a proprietary fungal system that offers higher productivity, lower costs, and a faster development timeline compared to the commonly used CHO system. Dyadic has collaborative research programs underway with companies like Sanofi and Mitsubishi Tanabe Pharma to evaluate C1 for producing various biologics. The company aims to license its C1 technology to partners in order to disrupt biomanufacturing and address the growing demand for more affordable biologic treatments.
COVID-19 Impacts on the Global mRNA Vaccines and Therapeutics Market NarayanSharma67
The “Global mRNA Vaccines and Therapeutics Market” is likely to grow at a CAGR of around 13% during the forecast period, i.e., 2021-26, says MarkNtel Advisors. The market growth essentially attributes to the rising prevalence of infectious and chronic diseases, including HIV, diabetes, cancer, and cardiovascular diseases.
Dyadic International is a global biotechnology company focused on improving and applying its proprietary C1 gene expression platform, a patented genetically modified strain of the fungus Myceliophthora thermophila, to address opportunities in human and animal health markets. The C1 platform can help bring biologic drugs to market faster, in greater volumes, and at lower cost than existing platforms like CHO cells. Dyadic pursues R&D collaborations and licensing arrangements to develop and manufacture biopharmaceuticals using the C1 platform.
Becton Dickinson & Company: VACUTAINER Systems DivisionZach Evans
Becton Dickinson & Company (BD) was formed in 1897 by Maxwell Becton and Fairleigh Dickinson as a medical device import company. In 1980, BD formed its VACUTAINER Systems Division (BDVS) to focus on blood collection products. By the mid-1980s, BDVS had an estimated 80% market share in the US but faced pressures from declining hospital testing and group purchasing organizations seeking single suppliers and private label products. BDVS needed to determine the best price and distribution strategy to address these market changes.
Leading Molecules to Market - An overview on licensingBananaIP Counsels
Leading Molecules to Market - An overview on licensing
Contact Us for Intellectual Property Services
BananaIP Counsels
Regd Office
No.40,3rd Main Road,JC Industrial Estate,
Kanakapura Road,Bangalore – 560 062.
Email: contact@bananaip.com
Telephone: +91-80-26860414 /24/34
Reducing technical and regulatory uncertinty in biosimilar developmentAjaz Hussain
Reducing risk of Biosimilar product development requires early attention to evidence development and effective communication to multiple stakeholders. Skill set for effective leadership and management, in the US market context, includes ability to: (1) Overcome the ‘blind spots’, (2) Analysis of knowledge, and (3) Evidence logic & communication. This presentation makes these points while comparing the EU and the USA regulatory context and the challenges of integration across multiple scientific and clinical disciplines.
The document discusses trends in the pharmaceutical industry through 2020. It notes ongoing challenges like unmet medical needs, aging populations, and chronic diseases. Future drivers include these aging and underserved populations in developing countries and effects of global warming. The industry will see more integrated value chains between pharma, payers, and providers. Treatment costs are unsustainable so the focus will shift to prevention and pharma providing full healthcare packages with payment for outcomes not just treatment. Pharma business models will change significantly, moving from blockbuster drug sales to more services across the healthcare spectrum. Laboratories of the future will need to develop new capabilities and talent to achieve this changed vision.
Diem Nguyen, regional president of North America for Global Established Pharmaceuticals at Goldman Sachs, presented at a biosimilars conference on April 2, 2015. The presentation discussed the attractive growth opportunity for biosimilars, with the market expected to reach $20 billion by 2020. It noted biosimilars have the potential to expand access to important medicines while providing savings to healthcare systems. However, biosimilars are complex to produce and require significant expertise in manufacturing. Pfizer believes policies should be based on science and physicians should have the ability to choose the treatment that is best for their patients. Pfizer is well positioned in the biosimilars space due to its capabilities and experience developing
Merck: Global Health and Access to MedicinesTony Sebastian
Merck is a global pharmaceutical company that developed many important drugs and vaccines. It faces issues in pricing policies, patents, and expanding access to medicine in developing countries with poor infrastructure and low incomes. Merck addresses these issues through initiatives like ACHAP in Botswana and Accelerating Access Initiative that provide HIV medicines at discounted prices. It also has a differential pricing policy that sets prices based on a country's development level and disease burden. Merck works to improve access while maintaining incentives for drug innovation through partnerships and tailored pricing strategies.
This is part of the MaRS BioEntrepreneurship series.
Speaker: Lynne Zydowsky, Ph.D., Managing Principal Zydowsky Consultants
* Explore the development of regulated drugs and devices
* Understand where and how value is generated in the pharmaceuticals industry
* Appreciate the interplay between science and business in a biotech company
To download a copy of the audio for this presentation, please go to:
http://www.marsdd.com/bioent/oct16
For the event blog and Q+A, please see:
http://blog.marsdd.com/2006/10/17/bringing-together-art-and-science/
- Biopharmaceutical manufacturing is undergoing a paradigm shift from unique, specialized production of individual products to more uniform, systematic production that can apply to multiple products. This increases manufacturing efficiency and the number of products that can be produced.
- Contract manufacturing is increasing and promises to open the pipeline for new biopharmaceuticals by reducing costs for innovators and increasing availability of products. Using contract manufacturers reduces financial risks for originators.
- Technological convergence has standardized cell culture and purification processes, allowing "one facility fits all" manufacturing that regulatory agencies now accept for contract manufacturing. This reduces costs and speeds development and availability of new products.
The document summarizes findings from interviews with 23 primary sources and 7 secondary sources regarding Teva Pharmaceutical Industries Ltd.'s ability to overcome increasing competition and the impending patent cliff for its top-selling drug Copaxone. Most sources believed Teva's growth initiatives would help, but strategic acquisitions would be key to success. Sources viewed Teva as a strong, innovative leader but said maintaining Copaxone patients and generic sales would be challenges without new blockbuster products or deals. While Teva's generic pipeline and sales were seen as promising, uncertainty remained around fending off competitors and retaining its share of the Copaxone market.
1. Biosimilar pathways have been established, many biologic patents will expire by 2025 exposing $33 billion in orphan drug sales to potential biosimilar competition. However, no true orphan biosimilars have reached the market yet due to challenges like rare disease patient recruitment for clinical trials.
2. Over the next decade, several monoclonal antibody orphan drugs will lose exclusivity including Soliris, Fabrazyme, and Pulmozyme. The first orphan biosimilar, Omnitrope for growth hormone deficiency, achieved 15% market share with a 40% price cut compared to the originator.
3. Regulators may consider relaxing clinical trial requirements for orphan biosimilars given small patient populations,
Genome Editing Market Analysis By Technology (CRISPR, TALEN, ZFN), By Delivery Method (Ex-vivo, In-vivo), By Application (Animal/Plant Cell Editing), By Service (In-house, Outsourced), By End-use And Segment Forecasts, 2018 - 2025
This document discusses the development of the biopharmaceuticals industry in India. It provides an overview of the characteristics and growth of the Indian biopharma market, which is valued at over $4 billion and growing 20-25% annually. It also outlines India's advantages for global R&D, including a skilled workforce, lower costs, and efficient clinical trials. The upcoming biosimilars opportunity from patent expiries is highlighted as a major driver. Challenges include financing difficulties and developing human resources excellence. Overall, the biopharma sector is one of India's fastest growing industries.
This document provides an overview of Merck, a global healthcare company. It discusses Merck's mission to save and improve lives through innovative pharmaceutical products and services. It outlines Merck's history and values, which include a commitment to ethics, access to medicines, and diversity. The document also discusses Merck's leadership, compliance programs, and views on issues like healthcare reform, innovation, and expanding global access to medicines and vaccines.
Global monoclonal antibodies market report 2017Chlue Reseach
McAbs has high targeting ability and can directly reach the diseased cells. Now McAbs are widely used in clinical practice with the unique advantages of reducing the damage of normal cells side effects.
The market share monoclonal antibody in global biopharmaceuticals has increased from 10% in 2000 to 42% in 2016.
It is the largest and fastest growing fine industry in the modern biopharmaceutical industry.
According to Chlue Research, the total sales of 52 kinds of McAbs approved by FDA were up to 99 billion US dollars in 2016, up 15% from 2015.
Content
McAbs Market
Biosimilars
Antineoplastic drugs
Autoimmune diseases
Ophthalmic remedy
PD-1 and PD-L1 McAbs
McAbs approved by FDA
BioEntrepreneurship: Intellectual Property: What Do Investors Look For?MaRS Discovery District
Strong patent protection is essential for a start-up biotechnology company and can be a valuable company asset. However, it is also expensive, with costs ranging from tens to hundreds of thousands of dollars over time. This session will focus on how to get the most out of your patent dollars.
This session presentation is available in audio format here: http://www.marsdd.com/bioent/dec4
wyeth Credit Suisse Group Healthcare Conferencefinance12
This document provides an overview of Wyeth's business, including its diversification across scientific platforms, business platforms, and therapeutic approaches. It discusses Wyeth's core biotech/vaccine franchises that have high growth potential, such as Enbrel and Prevnar. The document also summarizes Wyeth's investments in biomanufacturing infrastructure and its leadership in biotech manufacturing and process development. Wyeth's standardized technology platforms are highlighted as helping to improve existing products and drive efficiencies.
The document discusses Antares Pharma, a pharmaceutical company focused on developing self-injection drug/device products. It summarizes Antares' approved and development-stage products, including Tjet for growth hormone (partnered with Teva), Vibex MTX for rheumatoid arthritis, and Oxybutynin gel for overactive bladder (partnered with Watson). It highlights the advantages of Antares' injection technology and the market opportunities in biosimilars and specialty injectable drugs.
Vivos Inc. is developing RadioGel, a next-generation radiopharmaceutical device to treat cancer. The company plans to generate near-term revenue from veterinary clinics and international licensing while pursuing FDA approval for multiple human cancer indications. RadioGel consists of yttrium-90 phosphate particles delivered via a hydrogel vehicle that solidifies at body temperature. Vivos expects to begin sales to private veterinary clinics in 2018 and obtain international licensing revenue. The company is led by an experienced management team and advised by world-class medical and scientific boards regarding FDA approval and expanding RadioGel's applications to additional cancer types.
Innovation and entrepreneurship in biotechnology an intl perspective - d. h...sanguru1977
This document provides an introduction to innovation and entrepreneurship in biotechnology. It defines innovation as new products, services, processes or ideas that are novel to an organization. Innovation can take various forms, including technological versus non-technological, and product versus process innovation. The document scopes the focus of the book, which is on entrepreneurship and innovation processes that are important for new biotechnology firms. It emphasizes the importance of innovation and entrepreneurship for competitiveness in the biotechnology industry.
Cangene provides forward-looking statements that are subject to risks and uncertainties. The company's businesses are subject to risks that cannot be predicted or quantified, so past results may differ from future results expressed or implied in forward-looking statements. The document discusses various risks and uncertainties that could affect the company's results.
The document discusses Genentech's capacity planning needs to meet potential demand for their cancer drug Avastin. It provides background on Genentech's operations, manufacturing processes, and previous capacity expansions. It examines potential demand scenarios for Avastin and outlines options for expanding capacity, including building additional facilities or expanding existing plants. A decision is needed on building a new plant called CCP3 to ensure sufficient capacity through 2015 while balancing risks and costs.
OBI Pharma presentation at JP Morgan Healthcare Conference 2018Gus Adapon, ELS
The document contains a safe harbor statement regarding forward-looking statements and outlines 11 factors that could cause actual results to differ from forward-looking statements. It also notes that earnings growth statements are not profit forecasts. The presentation summarizes the 36th J.P. Morgan Annual Healthcare Conference, including key highlights on Adagloxad Simolenin such as constructive EOP2 meetings with regulators and a proposed global phase 3 trial design. It also provides updates on OBI's expanding oncology portfolio through passive immunotherapy, antibody drug conjugates, and small molecule programs.
The document discusses BioTime, Inc., a biotechnology company leading the regenerative medicine revolution. It summarizes BioTime's expertise in pluripotent stem cells and its focus on advancing two clinical programs - Renevia for facial aesthetics and OpRegen for dry age-related macular degeneration. It outlines upcoming milestones for these programs in 2016-2017, and how BioTime is unlocking value from its ownership stakes in public subsidiaries Asterias and OncoCyte, which are applying BioTime's stem cell technologies to therapies for conditions with high unmet medical need.
applied INSIGHTS: 10 year perspective on biosimilars, prediction for success ...Richard Littlewood
Biosimilars, approved highly similar versions of biologic medicines, are >10 years old now, in Europe
applied strategic has worked on strategy for biosimilars since 2007. In China, there is major potential for biosimilars industry success
The document discusses trends in the pharmaceutical industry through 2020. It notes ongoing challenges like unmet medical needs, aging populations, and chronic diseases. Future drivers include these aging and underserved populations in developing countries and effects of global warming. The industry will see more integrated value chains between pharma, payers, and providers. Treatment costs are unsustainable so the focus will shift to prevention and pharma providing full healthcare packages with payment for outcomes not just treatment. Pharma business models will change significantly, moving from blockbuster drug sales to more services across the healthcare spectrum. Laboratories of the future will need to develop new capabilities and talent to achieve this changed vision.
Diem Nguyen, regional president of North America for Global Established Pharmaceuticals at Goldman Sachs, presented at a biosimilars conference on April 2, 2015. The presentation discussed the attractive growth opportunity for biosimilars, with the market expected to reach $20 billion by 2020. It noted biosimilars have the potential to expand access to important medicines while providing savings to healthcare systems. However, biosimilars are complex to produce and require significant expertise in manufacturing. Pfizer believes policies should be based on science and physicians should have the ability to choose the treatment that is best for their patients. Pfizer is well positioned in the biosimilars space due to its capabilities and experience developing
Merck: Global Health and Access to MedicinesTony Sebastian
Merck is a global pharmaceutical company that developed many important drugs and vaccines. It faces issues in pricing policies, patents, and expanding access to medicine in developing countries with poor infrastructure and low incomes. Merck addresses these issues through initiatives like ACHAP in Botswana and Accelerating Access Initiative that provide HIV medicines at discounted prices. It also has a differential pricing policy that sets prices based on a country's development level and disease burden. Merck works to improve access while maintaining incentives for drug innovation through partnerships and tailored pricing strategies.
This is part of the MaRS BioEntrepreneurship series.
Speaker: Lynne Zydowsky, Ph.D., Managing Principal Zydowsky Consultants
* Explore the development of regulated drugs and devices
* Understand where and how value is generated in the pharmaceuticals industry
* Appreciate the interplay between science and business in a biotech company
To download a copy of the audio for this presentation, please go to:
http://www.marsdd.com/bioent/oct16
For the event blog and Q+A, please see:
http://blog.marsdd.com/2006/10/17/bringing-together-art-and-science/
- Biopharmaceutical manufacturing is undergoing a paradigm shift from unique, specialized production of individual products to more uniform, systematic production that can apply to multiple products. This increases manufacturing efficiency and the number of products that can be produced.
- Contract manufacturing is increasing and promises to open the pipeline for new biopharmaceuticals by reducing costs for innovators and increasing availability of products. Using contract manufacturers reduces financial risks for originators.
- Technological convergence has standardized cell culture and purification processes, allowing "one facility fits all" manufacturing that regulatory agencies now accept for contract manufacturing. This reduces costs and speeds development and availability of new products.
The document summarizes findings from interviews with 23 primary sources and 7 secondary sources regarding Teva Pharmaceutical Industries Ltd.'s ability to overcome increasing competition and the impending patent cliff for its top-selling drug Copaxone. Most sources believed Teva's growth initiatives would help, but strategic acquisitions would be key to success. Sources viewed Teva as a strong, innovative leader but said maintaining Copaxone patients and generic sales would be challenges without new blockbuster products or deals. While Teva's generic pipeline and sales were seen as promising, uncertainty remained around fending off competitors and retaining its share of the Copaxone market.
1. Biosimilar pathways have been established, many biologic patents will expire by 2025 exposing $33 billion in orphan drug sales to potential biosimilar competition. However, no true orphan biosimilars have reached the market yet due to challenges like rare disease patient recruitment for clinical trials.
2. Over the next decade, several monoclonal antibody orphan drugs will lose exclusivity including Soliris, Fabrazyme, and Pulmozyme. The first orphan biosimilar, Omnitrope for growth hormone deficiency, achieved 15% market share with a 40% price cut compared to the originator.
3. Regulators may consider relaxing clinical trial requirements for orphan biosimilars given small patient populations,
Genome Editing Market Analysis By Technology (CRISPR, TALEN, ZFN), By Delivery Method (Ex-vivo, In-vivo), By Application (Animal/Plant Cell Editing), By Service (In-house, Outsourced), By End-use And Segment Forecasts, 2018 - 2025
This document discusses the development of the biopharmaceuticals industry in India. It provides an overview of the characteristics and growth of the Indian biopharma market, which is valued at over $4 billion and growing 20-25% annually. It also outlines India's advantages for global R&D, including a skilled workforce, lower costs, and efficient clinical trials. The upcoming biosimilars opportunity from patent expiries is highlighted as a major driver. Challenges include financing difficulties and developing human resources excellence. Overall, the biopharma sector is one of India's fastest growing industries.
This document provides an overview of Merck, a global healthcare company. It discusses Merck's mission to save and improve lives through innovative pharmaceutical products and services. It outlines Merck's history and values, which include a commitment to ethics, access to medicines, and diversity. The document also discusses Merck's leadership, compliance programs, and views on issues like healthcare reform, innovation, and expanding global access to medicines and vaccines.
Global monoclonal antibodies market report 2017Chlue Reseach
McAbs has high targeting ability and can directly reach the diseased cells. Now McAbs are widely used in clinical practice with the unique advantages of reducing the damage of normal cells side effects.
The market share monoclonal antibody in global biopharmaceuticals has increased from 10% in 2000 to 42% in 2016.
It is the largest and fastest growing fine industry in the modern biopharmaceutical industry.
According to Chlue Research, the total sales of 52 kinds of McAbs approved by FDA were up to 99 billion US dollars in 2016, up 15% from 2015.
Content
McAbs Market
Biosimilars
Antineoplastic drugs
Autoimmune diseases
Ophthalmic remedy
PD-1 and PD-L1 McAbs
McAbs approved by FDA
BioEntrepreneurship: Intellectual Property: What Do Investors Look For?MaRS Discovery District
Strong patent protection is essential for a start-up biotechnology company and can be a valuable company asset. However, it is also expensive, with costs ranging from tens to hundreds of thousands of dollars over time. This session will focus on how to get the most out of your patent dollars.
This session presentation is available in audio format here: http://www.marsdd.com/bioent/dec4
wyeth Credit Suisse Group Healthcare Conferencefinance12
This document provides an overview of Wyeth's business, including its diversification across scientific platforms, business platforms, and therapeutic approaches. It discusses Wyeth's core biotech/vaccine franchises that have high growth potential, such as Enbrel and Prevnar. The document also summarizes Wyeth's investments in biomanufacturing infrastructure and its leadership in biotech manufacturing and process development. Wyeth's standardized technology platforms are highlighted as helping to improve existing products and drive efficiencies.
The document discusses Antares Pharma, a pharmaceutical company focused on developing self-injection drug/device products. It summarizes Antares' approved and development-stage products, including Tjet for growth hormone (partnered with Teva), Vibex MTX for rheumatoid arthritis, and Oxybutynin gel for overactive bladder (partnered with Watson). It highlights the advantages of Antares' injection technology and the market opportunities in biosimilars and specialty injectable drugs.
Vivos Inc. is developing RadioGel, a next-generation radiopharmaceutical device to treat cancer. The company plans to generate near-term revenue from veterinary clinics and international licensing while pursuing FDA approval for multiple human cancer indications. RadioGel consists of yttrium-90 phosphate particles delivered via a hydrogel vehicle that solidifies at body temperature. Vivos expects to begin sales to private veterinary clinics in 2018 and obtain international licensing revenue. The company is led by an experienced management team and advised by world-class medical and scientific boards regarding FDA approval and expanding RadioGel's applications to additional cancer types.
Innovation and entrepreneurship in biotechnology an intl perspective - d. h...sanguru1977
This document provides an introduction to innovation and entrepreneurship in biotechnology. It defines innovation as new products, services, processes or ideas that are novel to an organization. Innovation can take various forms, including technological versus non-technological, and product versus process innovation. The document scopes the focus of the book, which is on entrepreneurship and innovation processes that are important for new biotechnology firms. It emphasizes the importance of innovation and entrepreneurship for competitiveness in the biotechnology industry.
Cangene provides forward-looking statements that are subject to risks and uncertainties. The company's businesses are subject to risks that cannot be predicted or quantified, so past results may differ from future results expressed or implied in forward-looking statements. The document discusses various risks and uncertainties that could affect the company's results.
The document discusses Genentech's capacity planning needs to meet potential demand for their cancer drug Avastin. It provides background on Genentech's operations, manufacturing processes, and previous capacity expansions. It examines potential demand scenarios for Avastin and outlines options for expanding capacity, including building additional facilities or expanding existing plants. A decision is needed on building a new plant called CCP3 to ensure sufficient capacity through 2015 while balancing risks and costs.
OBI Pharma presentation at JP Morgan Healthcare Conference 2018Gus Adapon, ELS
The document contains a safe harbor statement regarding forward-looking statements and outlines 11 factors that could cause actual results to differ from forward-looking statements. It also notes that earnings growth statements are not profit forecasts. The presentation summarizes the 36th J.P. Morgan Annual Healthcare Conference, including key highlights on Adagloxad Simolenin such as constructive EOP2 meetings with regulators and a proposed global phase 3 trial design. It also provides updates on OBI's expanding oncology portfolio through passive immunotherapy, antibody drug conjugates, and small molecule programs.
The document discusses BioTime, Inc., a biotechnology company leading the regenerative medicine revolution. It summarizes BioTime's expertise in pluripotent stem cells and its focus on advancing two clinical programs - Renevia for facial aesthetics and OpRegen for dry age-related macular degeneration. It outlines upcoming milestones for these programs in 2016-2017, and how BioTime is unlocking value from its ownership stakes in public subsidiaries Asterias and OncoCyte, which are applying BioTime's stem cell technologies to therapies for conditions with high unmet medical need.
applied INSIGHTS: 10 year perspective on biosimilars, prediction for success ...Richard Littlewood
Biosimilars, approved highly similar versions of biologic medicines, are >10 years old now, in Europe
applied strategic has worked on strategy for biosimilars since 2007. In China, there is major potential for biosimilars industry success
Biosceptre is developing targeted cancer therapies directed at the nfP2X7 receptor, which is found in many cancer types but not healthy tissue. They have three drug candidates in clinical trials: BIL03s, a systemic antibody; BIL06v, a peptide vaccine; and BIL010t, a topical antibody for skin cancer. Biosceptre seeks to raise £25M for further development and has an experienced leadership team and intellectual property protecting its platform until the early 2030s.
Vivos Inc. presented a new brachytherapy tool called RadioGel for treating cancers in humans and animals. RadioGel consists of yttrium-90 phosphate particles delivered via a hydrogel vehicle. It is designed to deliver a high radiation dose directly to tumors while minimizing damage to healthy tissue. The company expects to generate near-term revenue from veterinary applications and international licensing as it pursues FDA approval for multiple human cancer indications starting with skin cancer. Vivos has strong leadership and advisors in place and an intellectual property protected platform technology to become an important new tool for cancer treatment.
The document provides an overview of Coherus BioSciences and their CHS-1701 pegfilgrastim biosimilar program. Key points include:
[1] CHS-1701 has completed a positive pivotal PK/PD study meeting all primary endpoints and demonstrating similar safety to Neulasta.
[2] Coherus has a strategic manufacturing agreement with KBI to support commercial launch and long-term supply of CHS-1701.
[3] The Neulasta market is very large at over $4B annually in the US and concentrated among a small number of buyers, making it well-suited for a biosimilar.
Biocon is proposing a market entry strategy into South Korea by forming a strategic alliance with LG Life Sciences. The key points of the strategy are:
1) South Korea was selected due to its strong biosimilars industry and supportive regulatory environment.
2) Biocon and LG Life Sciences will share risks and resources to gain competitive advantages like access to South Korea's sales and marketing networks and R&D capabilities.
3) The alliance will allow Biocon to enter the South Korean market faster with minimum risk and help understand the market better.
Biocon plans to enter the South Korean biosimilars market through a strategic alliance with LG Life Sciences. This will allow Biocon to gain access to LG's extensive sales and marketing network, R&D resources, and production facilities in South Korea. The key advantages of this alliance are reduced risks and costs for Biocon, as well as a faster entry into the South Korean market. Biocon will target the aging Korean population by focusing on affordable biosimilar drugs for diabetes, cancer, and cardiovascular diseases.
- The document outlines the agenda and speaker details for the 5th Biosimilars Congregation 2014 conference taking place on September 10th, 2014 in Mumbai, India.
- The conference will bring together leaders in the pharmaceutical, biotechnology, and regulatory fields to discuss challenges in biosimilar development and the evolving regulatory landscape.
- Key topics to be covered include assessing biosimilar similarity, strategic choices for biobetters and biosimilars, safety evaluation, regulatory updates, and emerging market opportunities for biosimilars in countries like India.
The document discusses Go-Life's strategy to expand from producing nutritional supplements to providing a more holistic approach to healthcare. It plans to do this through developing digital health platforms, medical devices, stem cell therapy, and partnerships in areas like frail care, clinics, and pharmacies. The goal is to shift from reactive disease management to preventative wellness and participate across the spectrum of changing healthcare focus areas.
Oncology biosimilars Market Report in PPT: Top Companies, Trends and Future D...IMARC Group
The document summarizes a report by IMARC Group on the global oncology biosimilars market. It discusses the growth of the market driven by the rising prevalence of cancer and upcoming patent expiries. Oncology biosimilars are similar to original biologics but are more affordable, improving access to treatment. The report analyzes the market by drug type, distribution channel, and region. It also profiles the major players in the industry.
applied strategic founder, Dr Richard Littlewood defined success factors for the next 10-year commercial phase of biosimilars at the 8th Biosimilars Congregation, held in London.
applied strategic founder, Dr Richard Littlewood defined success factors for the next 10-year commercial phase of biosimilars at the 8th Biosimilars Congregation, held in London.
Biobanking Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opport...IMARC Group
The global biobanking market size reached US$ 53.3 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 77.6 Billion by 2027, exhibiting a growth rate (CAGR) of 6.18% during 2022-2027.
More Info:- https://www.imarcgroup.com/biobanking-market
Future Watch summary: Future growth opportunities in global biobanks marketTeam Finland Future Watch
This Future Watch report compares the current status of forerunning biobanks in Finland, Denmark, Sweden, UK and USA, analyze the needs and views of key biobank customer segments as well as offer key recommendations for Finnish biobank to gain a larger footprint in the biobank market.
A presentation of Genentech strategic growth options vis-a-vis the current economic and structural challenges the biotech industry is facing.
Team project, December 2008.
This document provides an overview of Cancer Genetics, Inc. (CGI) and their focus on being an oncology diagnostics partner from bench to bedside. Some key points:
- CGI utilizes targeted acquisitions and collaborations with research institutions to expand their testing capabilities and global footprint.
- They have a proprietary portfolio of over 20 genomic tests and panels focused on cancers like blood cancers, lymphomas, lung cancer, and solid tumors.
- CGI partners with leading biopharma companies, supporting over 120 clinical trials with testing and services. They have contracts with 8 of the top 10 biopharma companies.
Similar to BioLife Solutions Investor Presentation - August 2017 (20)
This presentation by Thibault Schrepel, Associate Professor of Law at Vrije Universiteit Amsterdam University, was made during the discussion “Artificial Intelligence, Data and Competition” held at the 143rd meeting of the OECD Competition Committee on 12 June 2024. More papers and presentations on the topic can be found at oe.cd/aicomp.
This presentation was uploaded with the author’s consent.
Collapsing Narratives: Exploring Non-Linearity • a micro report by Rosie WellsRosie Wells
Insight: In a landscape where traditional narrative structures are giving way to fragmented and non-linear forms of storytelling, there lies immense potential for creativity and exploration.
'Collapsing Narratives: Exploring Non-Linearity' is a micro report from Rosie Wells.
Rosie Wells is an Arts & Cultural Strategist uniquely positioned at the intersection of grassroots and mainstream storytelling.
Their work is focused on developing meaningful and lasting connections that can drive social change.
Please download this presentation to enjoy the hyperlinks!
Carrer goals.pptx and their importance in real lifeartemacademy2
Career goals serve as a roadmap for individuals, guiding them toward achieving long-term professional aspirations and personal fulfillment. Establishing clear career goals enables professionals to focus their efforts on developing specific skills, gaining relevant experience, and making strategic decisions that align with their desired career trajectory. By setting both short-term and long-term objectives, individuals can systematically track their progress, make necessary adjustments, and stay motivated. Short-term goals often include acquiring new qualifications, mastering particular competencies, or securing a specific role, while long-term goals might encompass reaching executive positions, becoming industry experts, or launching entrepreneurial ventures.
Moreover, having well-defined career goals fosters a sense of purpose and direction, enhancing job satisfaction and overall productivity. It encourages continuous learning and adaptation, as professionals remain attuned to industry trends and evolving job market demands. Career goals also facilitate better time management and resource allocation, as individuals prioritize tasks and opportunities that advance their professional growth. In addition, articulating career goals can aid in networking and mentorship, as it allows individuals to communicate their aspirations clearly to potential mentors, colleagues, and employers, thereby opening doors to valuable guidance and support. Ultimately, career goals are integral to personal and professional development, driving individuals toward sustained success and fulfillment in their chosen fields.
This presentation by OECD, OECD Secretariat, was made during the discussion “Artificial Intelligence, Data and Competition” held at the 143rd meeting of the OECD Competition Committee on 12 June 2024. More papers and presentations on the topic can be found at oe.cd/aicomp.
This presentation was uploaded with the author’s consent.
Suzanne Lagerweij - Influence Without Power - Why Empathy is Your Best Friend...Suzanne Lagerweij
This is a workshop about communication and collaboration. We will experience how we can analyze the reasons for resistance to change (exercise 1) and practice how to improve our conversation style and be more in control and effective in the way we communicate (exercise 2).
This session will use Dave Gray’s Empathy Mapping, Argyris’ Ladder of Inference and The Four Rs from Agile Conversations (Squirrel and Fredrick).
Abstract:
Let’s talk about powerful conversations! We all know how to lead a constructive conversation, right? Then why is it so difficult to have those conversations with people at work, especially those in powerful positions that show resistance to change?
Learning to control and direct conversations takes understanding and practice.
We can combine our innate empathy with our analytical skills to gain a deeper understanding of complex situations at work. Join this session to learn how to prepare for difficult conversations and how to improve our agile conversations in order to be more influential without power. We will use Dave Gray’s Empathy Mapping, Argyris’ Ladder of Inference and The Four Rs from Agile Conversations (Squirrel and Fredrick).
In the session you will experience how preparing and reflecting on your conversation can help you be more influential at work. You will learn how to communicate more effectively with the people needed to achieve positive change. You will leave with a self-revised version of a difficult conversation and a practical model to use when you get back to work.
Come learn more on how to become a real influencer!
XP 2024 presentation: A New Look to Leadershipsamililja
Presentation slides from XP2024 conference, Bolzano IT. The slides describe a new view to leadership and combines it with anthro-complexity (aka cynefin).
This presentation by Nathaniel Lane, Associate Professor in Economics at Oxford University, was made during the discussion “Pro-competitive Industrial Policy” held at the 143rd meeting of the OECD Competition Committee on 12 June 2024. More papers and presentations on the topic can be found at oe.cd/pcip.
This presentation was uploaded with the author’s consent.
This presentation by Juraj Čorba, Chair of OECD Working Party on Artificial Intelligence Governance (AIGO), was made during the discussion “Artificial Intelligence, Data and Competition” held at the 143rd meeting of the OECD Competition Committee on 12 June 2024. More papers and presentations on the topic can be found at oe.cd/aicomp.
This presentation was uploaded with the author’s consent.
This presentation by OECD, OECD Secretariat, was made during the discussion “Pro-competitive Industrial Policy” held at the 143rd meeting of the OECD Competition Committee on 12 June 2024. More papers and presentations on the topic can be found at oe.cd/pcip.
This presentation was uploaded with the author’s consent.
This presentation by OECD, OECD Secretariat, was made during the discussion “Competition and Regulation in Professions and Occupations” held at the 77th meeting of the OECD Working Party No. 2 on Competition and Regulation on 10 June 2024. More papers and presentations on the topic can be found at oe.cd/crps.
This presentation was uploaded with the author’s consent.
This presentation by Professor Alex Robson, Deputy Chair of Australia’s Productivity Commission, was made during the discussion “Competition and Regulation in Professions and Occupations” held at the 77th meeting of the OECD Working Party No. 2 on Competition and Regulation on 10 June 2024. More papers and presentations on the topic can be found at oe.cd/crps.
This presentation was uploaded with the author’s consent.
Mastering the Concepts Tested in the Databricks Certified Data Engineer Assoc...SkillCertProExams
• For a full set of 760+ questions. Go to
https://skillcertpro.com/product/databricks-certified-data-engineer-associate-exam-questions/
• SkillCertPro offers detailed explanations to each question which helps to understand the concepts better.
• It is recommended to score above 85% in SkillCertPro exams before attempting a real exam.
• SkillCertPro updates exam questions every 2 weeks.
• You will get life time access and life time free updates
• SkillCertPro assures 100% pass guarantee in first attempt.